Novo Nordisk settles case of market manipulation, will pay USD 100m
Novo Nordisk and former executives Lars Rebien Sørensen, Jesper Brandgaard and Jakob Riis have reached a settlement in the lawsuit involving alleged market manipulation between 2015 and 2016.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
A US class action litigation, which since 2017 has been hanging over Novo Nordisk and its three former executives, Lars Rebien Sørensen, Jesper Brandgaard and Jakob Riis, now seems to have reached its conclusion, the company reports in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk creates new RNA and gene therapy unit
For subscribers
